Literature DB >> 11554889

Remission of seizures in a population-based adult cohort with a newly diagnosed unprovoked epileptic seizure.

H Lindsten1, H Stenlund, L Forsgren.   

Abstract

PURPOSE: To investigate the probability of achieving remission of seizures after a newly diagnosed unprovoked epileptic seizure in an adult population-based cohort.
METHODS: 107 patients aged 17 years or older with a newly diagnosed unprovoked epileptic seizure (index seizure) in 1985 through 1987 were followed up until the date of death or to the end of 1996. The proportion of cases during follow-up that attained a 1-year, 3-year, 5-year remission was calculated by actuarial analyses. Variables for stratification were age at diagnosis, seizure type, etiology, EEG, and the occurrence of seizures within 1 year of initiation of antiepileptic drug (AED) therapy.
RESULTS: Cumulative 1-, 3- and 5-year remission rates were 68, 64, and 58%. There was no statistically significant difference regarding time points of achieving a 1-year remission after epilepsy diagnosis and the subsequent probability during follow-up of attaining a 5-year remission. Having seizures within 1 year after beginning with an AED was a statistically significant predictor of never achieving 1-year remission of seizures during follow-up (refractory seizures). Other stratified variables were not statistically significant predictors.
CONCLUSIONS: Seizure prognosis for the majority of patients with newly diagnosed epilepsy is good. The time required after epilepsy diagnosis to achieve a 1-year remission of seizures does not affect the probability of additionally achieving a 5-year remission. Patients with refractory seizures can be identified within a few years from diagnosis of epilepsy. These patients must be targeted early for optimization of pharmacologic treatment, possible surgery, and psychosocial intervention.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11554889     DOI: 10.1046/j.1528-1157.2001.0420081025.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  14 in total

1.  Honing in on risk factors for prolonged remission off medication by reducing heterogeneity.

Authors:  Dale C Hesdorffer
Journal:  Epilepsy Curr       Date:  2012-05       Impact factor: 7.500

2.  Eight Flurothyl-Induced Generalized Seizures Lead to the Rapid Evolution of Spontaneous Seizures in Mice: A Model of Epileptogenesis with Seizure Remission.

Authors:  Sridhar B Kadiyala; Joshua Q Yannix; Julia W Nalwalk; Dominick Papandrea; Barbara S Beyer; Bruce J Herron; Russell J Ferland
Journal:  J Neurosci       Date:  2016-07-13       Impact factor: 6.167

3.  Remission and relapse in a drug-resistant epilepsy population followed prospectively.

Authors:  Brian Callaghan; Malka Schlesinger; William Rodemer; John Pollard; Dale Hesdorffer; W Allen Hauser; Jacqueline French
Journal:  Epilepsia       Date:  2011-01-26       Impact factor: 5.864

4.  Complete remission in nonsyndromic childhood-onset epilepsy.

Authors:  Anne T Berg; Francine M Testa; Susan R Levy
Journal:  Ann Neurol       Date:  2011-06-27       Impact factor: 10.422

Review 5.  Pharmacoresistance and the role of surgery in difficult to treat epilepsy.

Authors:  Samuel Wiebe; Nathalie Jette
Journal:  Nat Rev Neurol       Date:  2012-09-11       Impact factor: 42.937

Review 6.  The natural history of epilepsy: an epidemiological view.

Authors:  P Kwan; J W Sander
Journal:  J Neurol Neurosurg Psychiatry       Date:  2004-10       Impact factor: 10.154

Review 7.  Identification of pharmacoresistant epilepsy.

Authors:  Anne T Berg
Journal:  Neurol Clin       Date:  2009-11       Impact factor: 3.806

8.  The Repeated Flurothyl Seizure Model in Mice.

Authors:  Russell J Ferland
Journal:  Bio Protoc       Date:  2017-06-05

9.  Response to Early AED Therapy and Its Prognostic Implications.

Authors:  Jacqueline A. French
Journal:  Epilepsy Curr       Date:  2002-05       Impact factor: 7.872

10.  Clinical characterization of epilepsy of unknown cause in cats.

Authors:  A M Wahle; A Brühschwein; K Matiasek; K Putschbach; E Wagner; R S Mueller; A Fischer
Journal:  J Vet Intern Med       Date:  2013-11-16       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.